ClinicalTrials.gg
Enrolling by invitationNCT06044337AMETHYST LTEUpdated Aug 4, 2026

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

A Phase 3 interventional study of BIIB059 (litifilimab) in Subacute Cutaneous Lupus Erythematosus and Chronic Cutaneous Lupus Erythematosus, sponsored by Biogen. Enrolling by invitation at 104 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.

The study will enroll only those participants who have completed treatment with litifilimab in the parent study, 230LE301.

The main objective of the study is to learn more about the long-term safety of litifilimab.

The main question researchers want to answer is:

  • How many participants have adverse events and serious adverse events after taking litifilimab? Adverse events are health problems that may or may not be caused by the study drug.

Researchers will also learn more about the effect of litifilimab on CLE. They will do this by measuring the symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).

Researchers will look at how litifilimab and CLE affect the quality of life of participants using a group of questionnaires. They will also look at how litifilimab affects laboratory tests and how participants' immune systems respond to litifilimab.

The study will be done as follows:

  • The last visit of parent study 230LE301 will be the first visit of study 230LE305.
  • All participants will receive litifilimab as an injection under the skin once every 4 weeks. Both researchers and participants will know the dose and identity of the study drug.
  • Globally, the treatment period will last up to 208 weeks, or 4 years. Participants will have up to 53 study visits during this time.
Read the detailed description

The primary objective of the study is to evaluate the long-term safety and tolerability BIIB059 (litifilimab) in participants who completed the parent study 230LE301 (NCT05531565) with active subacute CLE and/or chronic CLE with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy.

The secondary objectives of the study are to evaluate the long-term effect of litifilimab on disease activity and the effect of litifilimab in preventing disease damage in participants with active subacute CLE and/or chronic CLE with or without systemic manifestations and refractory and/or intolerant to antimalarials; to evaluate the long-term effect of litifilimab on preventing lupus flare in participants with CLE with SLE; to assess long-term use of oral corticosteroid (OCS) in participants receiving litifilimab treatment; to assess the impact of litifilimab on participant-reported health-related quality of life (HRQoL); to evaluate long-term effect of litifilimab on laboratory parameters; to evaluate the immunogenicity and pharmacokinetics (PK) of litifilimab.

02

Conditions studied

  • Subacute Cutaneous Lupus Erythematosus
  • Chronic Cutaneous Lupus Erythematosus
03

In context

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

This study's planned enrollment of 306 is above the median of 32 across 57 interventional studies indexed under Lupus Erythematosus, Cutaneous.

Browse Lupus Erythematosus, Cutaneous studies →

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants who completed the parent study (230LE301 [NCT05531565], Part A or Part B) on study treatment (received treatment through Week 48 and attended the last study assessment visit at Week 52).
  • Ability of the participant to understand the purpose and risks of the study, to provide , and to authorize the use of confidential health information in accordance with national and local privacy regulations.

Key Exclusion Criteria:

  • Early Part A or Part B parent study (230LE301 [NCT05531565]) treatment terminators (participants who discontinued study treatment before Week 48).
  • Early Part A or Part B parent study terminators [participants who withdrew from parent study participation before Week 52 and did not complete the parent study extended treatment period (ETP)].
  • Participants who have developed any other medical diseases, conditions, or abnormalities, rendering their participation in the long-term extension (LTE) study unsuitable in the opinion of the Investigator.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
306 participants (estimated)

Study arms

  • Experimental
    BIIB059

    Participants will receive BIIB059 (litifilimab) subcutaneously (SC), once every 4 weeks up to Week 204 in the LTE period.

    Drug: BIIB059 (litifilimab)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 232 weeks

Secondary outcomes

  1. Percentage of Participants who Achieve a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI)-70 Response, Defined as a 70% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])

    Time frame: Up to 232 weeks

  2. Percentage of Participants who Achieve a CLASI-50 Response, Defined as a 50% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])

    Time frame: Up to 232 weeks

  3. Percentage of Participants who Achieve a CLASI-90 Response, Defined as a 90% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])

    Time frame: Up to 232 weeks

  4. Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1

    Time frame: Up to 232 weeks

  5. Percentage of Participants who Achieve a CLA-IGA-R Other Morphologic Characteristics (OMC) Score of 0

    Time frame: Up to 232 weeks

  6. Percentage of Participants With a CLASI-70 Response Among CLASI-70 Responders at Long-Term Extension (LTE) Baseline

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  7. Percentage of Participants With a CLASI-50 Response Among CLASI-50 Responders at LTE Baseline

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  8. Percentage of Participants With a CLASI-90 Response Among CLASI-90 Responders at LTE Baseline

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  9. Percentage of Participants With a CLA-IGA-R Erythema Score of 0 or 1 Among Participants With a CLA-IGA-R Erythema Score of 0 or 1 at LTE Baseline

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  10. Percentage of Participants With CLA-IGA-R OMC Score of 0 or 1 and at Least 1 Level of Improvement From Baseline Value(Parent Study) Among Participants With CLA IGA R OMC Score of 0 or 1 and at Least 1 Level Improvement From Baseline Value(Parent Study)

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  11. Percentage of Participants With a CLASI-70 Response Among CLASI-50 Responders at LTE Baseline

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  12. Percentage of Participants With Loss of Response, Defined as an Increase of ≥ 7 Points in CLASI-A Total Score From Baseline

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  13. Percentage of Participants who Achieve a CLASI A Score of 0 to 3

    Time frame: Up to 232 weeks

  14. Percentage of Participants who Achieve a CLASI-A Score of 0 to 5

    Time frame: Up to 232 weeks

  15. Percentage of Participants With a CLASI-A 0 to 3 Response Among CLASI-A 0 to 3 Responders at LTE Baseline

    Time frame: Day 1 (LTE Baseline) up to 232 weeks

  16. Absolute Change From Baseline in CLASI-A Score of Parent Study (NCT05531565) to Week 208

    Time frame: Day 1 (Baseline of Parent study) up to 208 weeks

  17. Percent Change From Baseline in CLASI-A Score of Parent Study (NCT05531565) to Week 208

    Time frame: Day 1 (Baseline of Parent study) up to 208 weeks

  18. Absolute Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index Damage (CLASI-D) Score From Baseline Value (Parent Study [NCT05531565]) to Week 208

    Time frame: Up to 208 weeks

  19. Percent Change in CLASI-D Score From Baseline Value (Parent Study [NCT05531565]) to Week 208

    Time frame: Up to 208 weeks

  20. Annualized Mild/Moderate and Severe Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index Flare Index (SFI) Rates

    Time frame: Up to 208 weeks

  21. Percentage of Participants With Oral Corticosteroid (OCS) Dose Among Participants who Used OCS at Baseline in the Parent Study (NCT05531565)

    Time frame: Day 1 (Baseline of Parent study) up to 208 weeks

  22. Percentage of Participants With OCS ≤ 7.5 Milligrams per day (mg/day) Among Participants who Used OCS at Baseline in the Parent Study (NCT05531565)

    Time frame: Day 1 (Baseline of Parent study) up to 208 weeks

  23. Percentage of Participants With OCS ≤ 5.0 mg/day Among Participants who Used OCS at Baseline in the Parent Study (NCT05531565)

    Time frame: Day 1 (Baseline of Parent study) up to 208 weeks

  24. Change From Baseline Value (Parent Study [NCT05531565]) in Cutaneous Lupus Erythematosus - Quality of Life (CLE-QoL) at Week 208

    Time frame: Baseline, Week 208

  25. Change From Baseline Value (Parent Study [NCT05531565]) in European Quality of Life - 5-Dimensions Questionnaire, 3-Level Version (EQ-5D-3L) at Week 104

    Time frame: Baseline, Week 104

  26. Change From Baseline Value (Parent Study [NCT05531565]) in 36-Item Short Form Survey (SF-36) (acute version) at Week 104

    Time frame: Baseline, Week 104

  27. Change From Baseline Value (Parent Study [NCT05531565]) in Work Productivity and Activity Impairment (WPAI): Lupus at Week 104

    Time frame: Baseline, Week 104

  28. Change From Baseline Value (Parent Study [NCT05531565]) in Patient Health Questionnaire-9 (PHQ-9) at Week 104

    Time frame: Baseline, Week 104

  29. Change From Baseline Value (Parent Study [NCT05531565]) in Subject Global Assessment of Skin - Follow-up (SGA-Skin-FU) at Week 208

    Time frame: Baseline, Week 208

  30. Change From Baseline Value (Parent Study [NCT05531565]) in Numerical Rating Scale (NRS) for Pain in Skin Rash at Week 208

    Time frame: Baseline, Week 208

  31. Change From Baseline Value (Parent Study [NCT05531565]) in Numerical Rating Scale (NRS) for Itch in Skin Rash at Week 208

    Time frame: Baseline, Week 208

  32. Number of Participants With Clinically Relevant Change From Baseline Value (Parent Study [NCT05531565]) in Standard Laboratory Parameters

    Time frame: Up to 208 weeks

  33. Number of Participants With Clinically Relevant Change From Baseline Value (Parent Study [NCT05531565]) in Electrocardiogram (ECG) Results

    Time frame: Up to 232 weeks

  34. Number of Participants With Anti-BIIB059 Antibodies in Serum

    Time frame: Up to 232 weeks

  35. Serum Concentration of Litifilimab

    Time frame: Pre-dose up to 232 weeks

07

Study locations

104 sites

Showing the first 100 of 104 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Jun 2029, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Sep 21, 2023
StartActual
Oct 3, 2023
Primary completionEst.
Jun 26, 2029
CompletionEst.
Dec 11, 2029
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06044337
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Oct 3, 2023
Primary completion
Jun 26, 2029 (estimated)
Completion
Dec 11, 2029 (estimated)
Last update
Aug 4, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Litifilimab

Start the discussion